Home> Products> special cases

{ "products": [ { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Imatinib IP 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2025-12-18T07:41:25.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-ip-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694004d8504825bb23fa3c1f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/100 mg", "description": "CONARIS T100 is a potent antifungal medication formulated with Terbinafine 250 mg and Itraconazole 100 mg. This combination tablet is designed to treat a wide range of fungal infections affecting the skin, nails, and other body parts. Terbinafine and Itraconazole work synergistically to eliminate fungi effectively by targeting their cell membranes and inhibiting growth, providing faster relief from symptoms such as itching, redness, scaling, and discomfort.\n\nFungal infections are common in humid climates and among individuals with compromised immunity, and medications like CONARIS T100 are essential for managing stubborn and recurrent infections. This combination therapy is often prescribed by dermatologists and healthcare professionals for moderate to severe fungal conditions.\n\nUses\n\nCONARIS T100 is used in the treatment of several fungal infections, including:\n\nDermatophytosis (Ringworm): Effective against infections of the skin, hair, and nails caused by dermatophytes.\n\nOnychomycosis (Nail Fungus): Helps in treating fungal infections of fingernails and toenails.\n\nTinea Infections: Treats tinea corporis, tinea cruris, and tinea pedis (athlete’s foot).\n\nCandidiasis: Useful in managing Candida infections affecting the skin and mucous membranes.\n\nRecurrent or Resistant Fungal Infections: Provides stronger antifungal action in cases not responsive to monotherapy.\n\nBenefits\n1. Broad-Spectrum Antifungal Action\n\nThe combination of Terbinafine and Itraconazole ensures effective activity against a wide variety of fungal species, including dermatophytes and yeasts.\n\n2. Faster Symptom Relief\n\nBy targeting fungi at multiple levels, CONARIS T100 helps relieve itching, redness, scaling, and discomfort more quickly than single-agent therapy.\n\n3. Treats Nail and Skin Infections\n\nTerbinafine penetrates nails effectively, while Itraconazole enhances the antifungal spectrum, making the combination ideal for nail and skin fungal infections.\n\n4. Reduces Recurrence\n\nCombination therapy decreases the risk of fungal infections returning by ensuring complete eradication of the pathogen.\n\n5. Convenient Dosage Form\n\nAvailable as an oral tablet, making it easy to administer and suitable for long-term treatment if prescribed.\n\nDosage\n\nAdults: Usually, one tablet of CONARIS T100 daily, preferably after meals, or as directed by a healthcare professional.\n\nTreatment Duration: Varies depending on the type and severity of infection; may range from 2 to 12 weeks for skin infections and longer for nail infections.\n\nImportant: Do not self-adjust dosage or stop treatment prematurely, as incomplete therapy can lead to recurrence or resistance.\n\nSide Effects\n\nCONARIS T100 is generally well tolerated when used as prescribed. Mild side effects may include:\n\nNausea or vomiting\n\nStomach upset or diarrhea\n\nHeadache\n\nDizziness\n\nSerious Side Effects (Rare)\n\nLiver enzyme elevation (monitoring recommended for long-term use)\n\nAllergic reactions such as rash, itching, or swelling\n\nSevere gastrointestinal discomfort\n\nConsult a healthcare provider immediately if you experience jaundice, persistent fatigue, or severe allergic reactions.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if prescribed by a doctor; safety during pregnancy is not fully established.\n\nLiver or Kidney Disorders: Dose adjustment or close monitoring may be required.\n\nDrug Interactions: Inform your doctor about all medications, especially antifungals, statins, or anticoagulants.\n\nAvoid Self-Medication: Fungal infections may mimic other skin conditions, so proper diagnosis is essential.\n\nAlcohol Consumption: Avoid alcohol as it may increase liver toxicity risk.\n\nStorage: Store in a cool, dry place away from direct sunlight and out of children’s reach.\n\nConclusion\n\nCONARIS T100, containing Terbinafine 250 mg and Itraconazole 100 mg, is a reliable and effective treatment for a wide spectrum of fungal infections, including skin, nail, and mucosal infections. Its dual-action antifungal mechanism provides faster symptom relief, reduces recurrence, and improves overall patient outcomes.\n\nWhen used under medical supervision and following prescribed dosage, CONARIS T100 offers a safe and convenient option for managing both common and stubborn fungal infections, ensuring better skin and nail health and enhanced quality of life.", "price": 184.0, "discountamount": 55.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2248, "imageuri": "https://productimages.withfloats.com/actual/694004da351fe1d6b98476e6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694004da351fe1d6b98476e6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:53:44.573Z", "updatedon": "2025-12-16T05:44:32.639Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-100-mg/2248", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T100", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole together", "terbinafine and itraconazole tablets uses", "terbinafine and itraconazole for nail fungus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400387893a9153e4bd58a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/200mg", "description": "CONARIS T200 is a potent antifungal combination tablet containing Terbinafine 250 mg and Itraconazole 200 mg, formulated to provide effective treatment for various fungal infections. Fungal infections of the skin, nails, and hair are common in India due to the hot and humid climate. These infections can cause itching, redness, scaling, and discomfort, affecting daily life and confidence.\n\nBy combining two powerful antifungal agents, CONARIS T200 targets fungal infections effectively, providing faster relief and improved recovery compared to monotherapy. Terbinafine works by inhibiting fungal cell growth, while Itraconazole disrupts fungal cell membrane formation, resulting in a comprehensive antifungal effect.\n\nUses\n\nCONARIS T200 is primarily prescribed for the management of:\n\nDermatophytosis (Ringworm, Tinea Infections)\nTreats fungal infections affecting skin, nails, and scalp.\n\nOnychomycosis (Fungal Nail Infection)\nHelps in eliminating nail fungus and promotes healthy nail growth.\n\nCandidiasis (Yeast Infections)\nEffective against mucocutaneous and superficial candidal infections.\n\nOther Superficial Fungal Infections\nUseful in treating skin infections caused by dermatophytes, yeasts, and other fungi.\n\nThis combination is particularly beneficial for chronic, resistant, or recurrent fungal infections.\n\nBenefits\n1. Broad-Spectrum Antifungal Activity\n\nThe dual action of Terbinafine and Itraconazole ensures effectiveness against a wide range of fungi, providing comprehensive treatment.\n\n2. Faster Symptom Relief\n\nPatients experience reduced itching, redness, scaling, and discomfort sooner than with single antifungal therapy.\n\n3. Promotes Healing\n\nSupports the restoration of healthy skin and nails, improving appearance and comfort.\n\n4. Reduces Recurrence\n\nThe combination therapy helps prevent fungal infections from returning, especially in chronic or resistant cases.\n\n5. Convenient Oral Administration\n\nOnce- or twice-daily tablet dosing improves patient compliance compared to topical treatments.\n\n6. Suitable for Adults\n\nFormulated for adult patients suffering from persistent fungal infections that require systemic therapy.\n\nDosage\n\nThe recommended dose of CONARIS T200 is usually one tablet once daily, or as directed by a physician.\n\nDuration of therapy depends on the type and severity of infection:\n\nSkin infections: Typically 2–4 weeks\n\nNail infections: May require 6–12 weeks or longer for full recovery\n\nImportant Instructions:\n\nSwallow the tablet whole with water.\n\nTake the medicine after food to reduce stomach upset.\n\nDo not skip doses and complete the full course even if symptoms improve.\n\nAlways follow the prescribing doctor’s instructions to ensure optimal results.\n\nSide Effects\n\nCONARIS T200 is generally well-tolerated, but some patients may experience mild side effects:\n\nNausea and vomiting\n\nStomach discomfort or indigestion\n\nHeadache\n\nDizziness\n\nSerious but Rare Side Effects\n\nLiver function disturbances\n\nAllergic reactions such as rash or swelling\n\nSevere gastrointestinal discomfort\n\nIf any unusual or severe symptoms appear, consult a healthcare professional immediately.\n\nPrecautions and Warning\n\nLiver and Kidney Disorders: Use with caution; liver function tests may be recommended during therapy.\n\nPregnancy and Breastfeeding: Consult your doctor before use; safety has not been fully established.\n\nDrug Interactions: Inform your doctor about other medications, particularly antacids, anticoagulants, or statins.\n\nAllergy: Avoid if allergic to Terbinafine, Itraconazole, or any other ingredient in the tablet.\n\nAlcohol Consumption: Limit alcohol intake, as it may increase the risk of liver-related side effects.\n\nConclusion\n\nCONARIS T200 (Terbinafine 250 mg + Itraconazole 200 mg) is an effective and trusted antifungal combination for the treatment of a variety of superficial and chronic fungal infections. By targeting fungi through dual mechanisms, it provides faster relief, promotes healing, and helps prevent recurrence. With proper dosing, adherence to medical advice, and monitoring for side effects, CONARIS T200 offers a comprehensive solution for adults dealing with persistent fungal infections, helping restore healthy skin, nails, and overall comfort.", "price": 204.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2247, "imageuri": "https://productimages.withfloats.com/actual/69400389f34633ae3de3f8f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400389f34633ae3de3f8f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:48:07.707Z", "updatedon": "2025-12-16T05:48:08.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-200mg/2247", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T200", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole", "terbinafine and itraconazole combination", "terbinafine and itraconazole together", "Fungal infections of the skin", "helping restore healthy skin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693c0c9c0c30ac5c9f8203b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Isosorbide Mononitrate IP 30mg Tablets", "description": "CARDULES ISMN SR 30 tablets provide sustained-release Isosorbide Mononitrate IP 30mg, a nitrate medication designed for long-term management of angina in patients with coronary artery disease. This formulation from Steris Healthcare Pvt Ltd ensures steady vasodilation to improve heart blood flow and reduce chest pain episodes. It supports daily activities by minimizing oxygen demand on the heart muscle.​\nProduct Overview\nCARDULES ISMN SR 30 contains Isosorbide Mononitrate IP 30mg in a sustained-release matrix, allowing once-daily dosing for consistent therapeutic levels over 12-24 hours. The tablet's extended-release technology prevents peak-trough fluctuations common in immediate-release forms, promoting better patient compliance. Each film-coated tablet delivers precise bioavailability, with the active metabolite nitric oxide activating guanylate cyclase to boost cyclic GMP, relaxing vascular smooth muscle primarily in veins.​\n\nThis mechanism reduces preload (venous return to the heart) and afterload (arterial resistance), easing cardiac workload without significantly affecting heart rate. Unlike short-acting nitrates for acute relief, CARDULES ISMN SR 30 targets prophylaxis in chronic stable angina, often prescribed alongside beta-blockers or calcium channel blockers. Available in strips of 10 tablets, it undergoes rigorous quality testing at Steris facilities to meet IP standards, ensuring purity and stability.​\n\nKey Uses\nCARDULES ISMN SR 30 primarily prevents angina pectoris in coronary artery disease, where narrowed vessels limit oxygen supply during exertion. Patients experience fewer chest pain attacks during walking, climbing stairs, or stress.​\n\nIt manages chronic stable angina by enhancing myocardial perfusion, suitable for long-term therapy in adults over 18. Healthcare providers may use it adjunctively for coronary spasm or post-myocardial infarction prophylaxis to stabilize symptoms.​\n\nIn select cases, it aids heart failure management by offloading the heart, though not as monotherapy. Always initiate under cardiology supervision with dose titration to tolerance.​\n\nMajor Benefits\nThe sustained-release profile offers 24-hour protection with single morning dosing, improving adherence and lifestyle quality for active patients. It boosts exercise tolerance by 20-30% in trials, allowing longer physical efforts without angina onset.​\n\nBy dilating vessels, it decreases ischemia risk, potentially lowering hospitalization rates for acute episodes. Compared to placebo, users report halved attack frequency within weeks, enhancing daily productivity and emotional well-being.​\n\nBenefit\tMechanism\tPatient Outcome\nAngina Prevention\tVasodilation reduces preload/afterload ​\tFewer attacks, better exertion capacity\nSteady Relief\tSR formulation maintains levels ​\tOnce-daily convenience, no fluctuations\nHeart Protection\tImproves O2 delivery ​\tReduced ischemia, enhanced QoL\nCompliance Boost\tSimple regimen ​\tHigher adherence vs multiple doses\nAdditional perks include minimal impact on blood pressure in normotensives and compatibility with anti-anginals, making it versatile in combo therapy.\n\nPotential Side Effects\nCommon effects include headache (dose-related, often transient in first week), dizziness, or flushing due to vasodilation—hydrate and rise slowly to manage. Gastrointestinal upset like nausea occurs in 5-10% initially.​\n\nOrthostatic hypotension risks fainting, especially early; avoid alcohol or other vasodilators. Rare serious issues encompass severe hypotension, tachycardia, or methemoglobinemia with overdose—monitor blood pressure regularly.​\n\nAllergic reactions (rash, itching) or vision changes warrant discontinuation. Contraindicated in hypotension, glaucoma, or recent PDE5 inhibitor use; caution in anemia or hypothyroidism.​\n\nDosage Guidelines\nStart with 30mg once daily upon waking, swallowed whole without crushing. Titrate to 60mg if tolerated after 3-7 days, max 120mg/day. Take on empty stomach for optimal absorption; avoid late dosing to prevent nocturnal headaches.​\n\nAdjust for elderly or renal/hepatic impairment. Tolerance may develop—nitrate-free interval (evening) helps sustain efficacy. Store below 30°C.​\nConclusion\nCARDULES ISMN SR 30 empowers angina patients with reliable, once-daily prevention, restoring confidence in routine activities under Steris Healthcare's quality assurance. Its targeted vasodilation balances efficacy and tolerability for sustained heart health", "price": 65.0, "discountamount": 19.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2243, "imageuri": "https://productimages.withfloats.com/actual/693c0ca6391a3fa44b0608d8.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0ca6391a3fa44b0608d8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:37:48.92Z", "updatedon": "2025-12-12T12:37:48.92Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/isosorbide-mononitrate-ip-30mg-tablets/2243", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CARDULES ISMN SR 30", "category": "", "tags": [ "Isosorbide Mononitrate IP 30mg Tablets", "coronary artery disease", "heart blood flow and reduce chest pain episodes", "oxygen demand on the heart muscle", "relaxing vascular smooth muscle primarily in veins" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693c0a0eb7439f8802544bc8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RIBAVIRIN CAPSULES IP 100mg", "description": "REBATERIS 100 contains Ribavirin IP 100mg in a hard gelatin capsule filled with white to off-white powder for optimal stability and bioavailability. Each pack typically includes 30 capsules, designed for oral administration with food to enhance absorption and reduce gastrointestinal upset. Ribavirin, a synthetic guanosine nucleoside analog, interferes with viral RNA polymerase and mRNA capping, halting hepatitis C virus (HCV) replication at multiple stages. This broad-spectrum antiviral also shows activity against respiratory syncytial virus (RSV) in select pediatric cases, though its primary indication remains HCV genotype management.​\n\nThe 100mg strength allows for weight-based dosing adjustments, making REBATERIS 100 suitable for adults and children over 3 years under specialist supervision. Unlike higher 200mg capsules, it supports finer dose reductions during therapy to manage side effects, ensuring better tolerability. Stored at room temperature away from moisture, it maintains potency for extended shelf life, aligning with pharmacopeial standards for purity and dissolution.​\n\nKey Uses\nREBATERIS 100 treats chronic hepatitis C virus infection in combination therapies, particularly for patients ineligible for all-oral direct-acting antivirals. It boosts sustained virologic response rates when paired with pegylated interferon alfa, addressing genotypes 1 through 6 based on regional guidelines.​\n\nIn severe RSV lower respiratory tract infections, off-label use occurs in hospitalized infants, where aerosolized forms predominate, but oral REBATERIS 100 contributes to interferon combos for immunocompromised children. It curbs viral load, prevents liver fibrosis progression, and reduces cirrhosis risk, making it essential for long-term liver preservation.​\n\nAdditionally, emerging evidence supports its adjunct role in certain hemorrhagic fevers like Lassa virus, though availability limits widespread application. Always initiated by hepatologists, treatment durations span 24-48 weeks depending on genotype, viral load, and response milestones.​\n\nMajor Benefits\nREBATERIS 100 enhances viral clearance, achieving up to 50-80% sustained response rates in interferon combinations, significantly lowering hepatocellular carcinoma risk over five years. Patients experience normalized liver enzymes and fibrosis regression on biopsy follow-up.​\n\nIts oral capsule form simplifies adherence compared to injectables, with twice-daily dosing fitting daily routines. The 100mg potency permits precise titration—e.g., 800-1400mg daily divided—for personalized therapy, minimizing excess exposure in lighter patients.​\n\nLong-term, it preserves liver function, averting transplants and improving quality of life metrics like fatigue reduction and work productivity. Cost-effective for resource-limited settings, REBATERIS 100 bridges gaps until pan-genotypic regimens become accessible.​\nBenefit\tMechanism\tClinical Impact\nViral Suppression\tRNA polymerase inhibition ​\t>50% SVR in combos ​\nLiver Protection\tFibrosis halt ​\tReduced cirrhosis by 30-40%\nFlexible Dosing\t100mg increments ​\tBetter tolerability, adherence\nBroad Genotype Coverage\tMulti-genotype efficacy ​\tVersatile for diverse patients\nPotential Side Effects\nCommon side effects include hemolytic anemia, peaking at weeks 4-8, necessitating hemoglobin monitoring and dose cuts to 600mg daily if levels drop below 10g/dL. Fatigue, headache, and insomnia affect over 40% of users, often resolving post-therapy.​\n\nGastrointestinal issues like nausea, diarrhea, and anorexia occur in 20-30%, mitigated by food intake. Dermatologic reactions—rash, pruritus—or flu-like symptoms from interferon pairing demand vigilance. Teratogenicity risks are high; dual contraception is mandatory for 6 months post-treatment due to sperm/ovum mutagenicity.​\n\nSerious risks encompass pulmonary infiltrates, cardiac ischemia in vulnerable patients, and thyroid dysfunction. Avoid in hemoglobinopathies, severe renal impairment (CrCl <50mL/min), or pregnancy. Regular blood counts and ophthalmologic exams guide safe continuation.​\n\nDosage Guidelines\nDosing is weight-based: adults <75kg receive mg/day (10 capsules: 5 AM, 5 PM); ≥75kg get 1200 mg/day (12 capsules: 6 AM, 6 PM), swallowed whole with meals. Pediatrics (≥3 years): 15mg/kg/day divided BID, rounded to the nearest 100mg via REBATERIS 100 capsules.​\n\nReduce by 200-400mg for anemia or neutropenia; discontinue if unresolved. Duration: 48 weeks for genotype 1, 24 weeks for others, with viral load checks at week 12. Swallow intact; no crushing.​\nConclusion\nREBATERIS 100 empowers hepatitis C management with proven antiviral potency and dosing precision from Steris Healthcare. It transforms prognosis for countless patients, but demands specialist oversight amid monitoring needs", "price": 2900.0, "discountamount": 870.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2242, "imageuri": "https://productimages.withfloats.com/actual/693c0a151c130ff8f4cd2c93.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0a151c130ff8f4cd2c93.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:26:54.651Z", "updatedon": "2025-12-12T12:26:54.651Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/ribavirin-capsules-ip-100mg/2242", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "REBATERIS 100", "category": "Gastroenterology", "tags": [ "Ribavirin IP 100mg", "HCV genotype management", "hepatitis C virus (HCV)", "RNA polymerase and mRNA capping", "respiratory tract infections", "fibrosis progression", "enzymes and fibrosis regression on biopsy" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693c05831844c6739ab3e83a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Mefenamic Acid and Paracetamol Suspension", "description": "METAPECT MF KID SUSPENSION stands out as a specialized formulation from Steris Healthcare Pvt Ltd, blending Mefenamic Acid, a non-steroidal anti-inflammatory drug (NSAID), with Paracetamol, a widely used analgesic and antipyretic. Typically available in a 60ml bottle with child-friendly flavoring, it contains precise concentrations like 100mg Mefenamic Acid and 250mg Paracetamol per 5ml serving, ensuring accurate dosing via the included measuring cup. This sugar-free or low-sugar variant minimizes dental risks while providing rapid absorption for faster onset compared to solid forms. Manufactured under stringent quality controls, it supports pediatric care by addressing inflammation at its source through COX enzyme inhibition, which curbs prostaglandin production responsible for pain signals and fever response.​\n\nThe suspension's dual-action mechanism sets it apart: Paracetamol targets the brain's hypothalamus to regulate body temperature and elevate pain thresholds, while Mefenamic Acid reduces tissue swelling and inflammatory mediators. This synergy makes METAPECT MF KID SUSPENSION more effective than single-ingredient options for multifaceted symptoms. Healthcare professionals often recommend it for short-term use in infants over six months and children, always under medical guidance to match age and weight-based dosages.​\n\nKey Uses\nMETAPECT MF KID SUSPENSION excels in managing fever associated with viral infections, teething, or post-vaccination reactions. It swiftly lowers elevated temperatures, promoting comfort and better sleep for restless kids.​\n\nFor pain relief, it tackles mild to moderate discomfort from headaches, toothaches, earaches, and sore throats common during colds or flu. Caregivers report noticeable easing of symptoms within 30-60 minutes, allowing children to resume play or eat without distress.​\n\nAdditionally, it soothes body aches, muscle strains from minor injuries, or joint pains in growing kids. In cases of post-surgical recovery or inflammatory episodes, it provides reliable support without the need for stronger opioids.​\n\nMajor Benefits\nThe primary benefit lies in its comprehensive symptom control, combining antipyretic, analgesic, and anti-inflammatory effects for holistic relief. Children experience reduced fever, less pain, and diminished swelling, leading to improved appetite and activity levels.​\n\nIts liquid suspension format ensures easy administration—no choking risks—and precise dosing prevents under- or overdosing. Flavored options like mango enhance compliance, turning medicine time into a less daunting routine for picky eaters.​\n\nCompared to alternatives, METAPECT MF KID SUSPENSION offers quicker bioavailability due to its oral liquid state, ideal for emergencies like high fever spikes at night. Long-term, it supports faster recovery by minimizing inflammation, potentially shortening illness duration when used as directed.​\n\nBenefit\tDescription:\tAdvantage over Single Agents\nFever Reduction\tLowers temperature via hypothalamic action ​\tFaster than Paracetamol alone\nPain Relief\tBlocks pain signals and prostaglandins. ​\tSuperior for inflammatory pain\nAnti-Inflammatory\tReduces swelling in tissues ​\tAddresses root cause, not just symptoms\nEasy Dosing\tLiquid with dropper for accuracy ​\tChild-friendly, no splitting tablets\nPotential Side Effects\nWhile generally well-tolerated, METAPECT MF KID SUSPENSION may cause mild gastrointestinal issues like nausea, vomiting, stomach pain, or indigestion in some children, especially if taken on an empty stomach. Administering with food can mitigate this.​\n\nLess common effects include drowsiness, dizziness, or allergic reactions such as rashes, itching, or swelling—seek immediate medical help if these occur. Prolonged use risks liver strain from Paracetamol or kidney concerns from Mefenamic Acid, so adhere strictly to prescribed durations.​\nRarely, it might lead to diarrhea, headache, or elevated liver enzymes. Monitoring is key; consult a doctor for persistent symptoms or in kids with pre-existing conditions like asthma or ulcers.​\n\nDosage Guidelines\nFollow pediatrician-recommended doses based on weight: typically 5-10ml every 6-8 hours, not exceeding 4 doses daily. Shake well before use and store below 30°C away from light.​\nAvoid in neonates under 6 months or those with hypersensitivity. Hydration and diet play roles in efficacy—pair with plenty of fluids.​\nConclusion\nMETAPECT MF KID SUSPENSION empowers parents with a dependable tool for childhood pain and fever, blending efficacy, safety, and convenience under Steris Healthcare's trusted banner. Quick relief restores normalcy, but professional oversight ensures optimal outcomes.", "price": 57.0, "discountamount": 18.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2241, "imageuri": "https://productimages.withfloats.com/actual/693c05860443b6722a4db029.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c05860443b6722a4db029.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:07:31.874Z", "updatedon": "2025-12-12T12:07:31.874Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/mefenamic-acid-and-paracetamol-suspension/2241", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "METAPECT MF KID SUSPENSION", "category": "PEDIATRICS", "tags": [ "Mefenamic Acid and Paracetamol Suspension", "Paracetamol", "Mefenamic Acid and 250mg Paracetamol per 5ml serving", "COX enzyme inhibition", "pain and fever", "Pain Relief" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6937c2a25e5aca52da7cb29f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Favipiravir 200mg", "description": "Favipiravir 200mg is an antiviral medication widely used to treat viral infections, particularly those caused by RNA viruses. It has gained significant attention in recent years as a promising therapeutic agent, especially during viral outbreaks such as influenza and more recently, COVID-19. This detailed description covers the product overview, its uses, key benefits, potential side effects, and a concluding summary to help users better understand Favipiravir 200mg.\n\nProduct Description\nFavipiravir belongs to a class of antiviral drugs that inhibit the replication of RNA viruses by targeting viral RNA-dependent RNA polymerase—an enzyme vital for viral replication. The 200mg dosage formulation is designed for oral administration and is typically available as film-coated tablets. The drug works by interfering with the viral genome synthesis process, thereby limiting the ability of viruses to multiply and spread in the body.\n\nOriginally developed and approved in Japan for the treatment of novel influenza strains, Favipiravir has since been explored and authorized in multiple countries for off-label or emergency use against other viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nUses of Favipiravir 200mg\nFavipiravir is primarily used as an antiviral treatment for infections caused by RNA viruses. Its key applications include:\n\nInfluenza Treatment: Favipiravir is effective against various strains of influenza viruses, especially when other antiviral medications prove less effective due to resistance or outbreak severity.\n\nCOVID-19 Management: During the COVID-19 pandemic, Favipiravir was rapidly adopted as part of many treatment protocols globally. It is used to manage mild to moderate COVID-19 cases by reducing viral load and accelerating recovery time.\n\nEmerging Viral Diseases: Favipiravir’s broad-spectrum antiviral activity makes it a potential treatment for other emerging RNA virus outbreaks, including Ebola, Lassa fever, and other viral hemorrhagic fevers.\n\nThe drug is typically prescribed by healthcare professionals after confirmed diagnosis and assessment of viral infection severity. Treatment duration and dosage depend on the specific infection and patient profile.\n\nKey Benefits of Favipiravir 200mg\nFavipiravir offers several important benefits that contribute to its growing role in viral infection management:\n\nBroad-Spectrum Antiviral Activity: Favipiravir targets a wide array of RNA viruses, making it versatile for treating multiple infections beyond influenza.\n\nOral Administration: Its oral tablet form facilitates ease of use in outpatient settings, reducing the burden on hospital resources and enabling home-based treatment.\n\nRapid Viral Load Reduction: Clinical studies indicate that Favipiravir can significantly decrease viral replication rates, thereby reducing the duration and severity of symptoms.\n\nPotential to Limit Disease Progression: Early treatment with Favipiravir may prevent progression to severe disease stages, especially in viral respiratory infections such as COVID-19.\n\nEmergency and Compassionate Use Flexibility: During health crises, Favipiravir has been approved under emergency use protocols, making it accessible when other options are limited.\n\nPotential Side Effects of Favipiravir 200mg\nWhile Favipiravir is generally well-tolerated, users should be aware of possible side effects. Reported adverse effects range from mild to moderate in severity and often resolve after treatment completion:\n\nGastrointestinal Disturbances: Nausea, vomiting, diarrhea, and abdominal discomfort may occur but are usually transient.\n\nElevated Liver Enzymes: Temporary increases in liver function tests have been reported, necessitating monitoring especially in patients with preexisting liver conditions.\n\nElevated Uric Acid Levels: Favipiravir can cause hyperuricemia; monitoring uric acid levels is advisable during treatment.\n\nHypersensitivity Reactions: Rare cases of allergic reactions, including rash, itching, or swelling, have been documented.\n\nTeratogenicity and Contraindications in Pregnancy: Favipiravir is contraindicated in pregnant women or those planning pregnancy due to potential risks of fetal harm observed in animal studies.\n\nPatients should inform their healthcare providers of all preexisting conditions and concomitant medications to avoid drug interactions and complications. Routine blood tests may be conducted to monitor liver function and uric acid levels during therapy.\n\nConclusion\nFavipiravir 200mg serves as a vital antiviral agent with broad-spectrum activity against RNA viruses, playing a significant role in managing viral infections like influenza and COVID-19. Its ability to reduce viral replication rapidly and its oral administration mode make it a convenient and effective option, particularly in outpatient or emergency settings. While side effects are generally manageable, careful patient monitoring ensures safe use, especially in vulnerable populations.\n\nAs viral epidemics and pandemics continue to challenge global health, Favipiravir remains an important therapeutic tool, helping to curb disease progression and improve patient outcomes. Consulting a healthcare professional before starting Favipiravir treatment is essential to determine appropriateness, dosage, and duration based on individual health status and specific viral infection.", "price": 1786.0, "discountamount": 536.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2238, "imageuri": "https://productimages.withfloats.com/actual/6937c2a56743e47449a24df1.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6937c2a56743e47449a24df1.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-09T06:33:06.62Z", "updatedon": "2025-12-09T06:33:06.62Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/favipiravir-200mg/2238", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "FAVIPRIVE 200", "category": "GENERAL RANGE", "tags": [ "Favipiravir 200mg", "RNA viruses", "Favipiravir 200mg", "COVID-19", "respiratory syndrome coronavirus 2 (SARS-CoV-2).", "Favipiravir targets a wide array of RNA viruses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693410b5de5d3e57a934024e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Levosalbutamol Respiratory Solution 0.31 mg ", "description": "THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg delivers targeted bronchodilation through nebulization, making it an essential therapy for asthma, COPD, and acute bronchospasm in adults and children. This low-dose formulation of the active R-isomer of salbutamol relaxes airway muscles swiftly, improving airflow and reducing symptoms like wheezing and shortness of breath. Ideal for patients needing gentle yet effective respiratory support, it ensures deep lung delivery via fine mist for optimal efficacy.​\n\nKey Uses of THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg\nTHEO-SLO LEVO LD addresses obstructive airway diseases by directly targeting bronchial constriction. Primary indications include acute asthma attacks, chronic bronchitis, emphysema, and exercise-induced symptoms, where it restores normal breathing patterns efficiently.​\n\nAsthma Management: Relieves wheezing, chest tightness, and breathlessness during flare-ups or as maintenance therapy.​\n\nCOPD Support: Eases airflow restriction in chronic bronchitis and emphysema, enhancing daily activities.​\n\nAcute Bronchospasm: Provides fast intervention for triggers like allergens, infections, or pollutants.​\n\nExercise-Induced Relief: Prevents airway narrowing during physical exertion.​\n\nPediatric and Elderly Use: Nebulizer-friendly for young children or those unable to use inhalers.​\n\nAdministered via nebulizer, dilute as prescribed (typically 0.31 mg in 2-3 ml saline) for 5-10 minute sessions, 2-4 times daily based on severity.​\n\nKey Benefits of THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg\nAs the purified R-isomer, Levosalbutamol in THEO-SLO LEVO LD offers higher potency and fewer side effects than racemic salbutamol, with rapid onset within minutes. Its nebulized form penetrates deeper into lungs, making it superior for severe cases or coordination-challenged patients.​\n\nQuick Bronchodilation: Relaxes smooth muscles to open airways, improving oxygen intake immediately.​\n\nEnhanced Tolerability: Lower cardiac stimulation reduces tachycardia risk compared to standard albuterol.​\n\nPatient-Friendly Delivery: Mist form suits infants, seniors, and acute distress without coordination needs.​\n\nSymptom Control: Decreases cough frequency, wheezing intensity, and respiratory distress for better quality of life.​\n\nLonger Relief Duration: Sustained action supports maintenance therapy alongside controllers like steroids.​\n\nClinical use shows improved lung function (FEV1 increase by 20-30%) and reduced hospitalization rates in responsive patients.​\n\nPotential Side Effects and Precautions for THEO-SLO LEVO LD\nTHEO-SLO LEVO LD remains well-tolerated at 0.31 mg, with most effects mild and transient. Monitor during initial use, especially in cardiac patients.​\n\nCommon Mild Effects: Tremors, nervousness, headache, or mild palpitations resolving quickly.​\n\nLess Frequent: Dry mouth, throat irritation, or muscle cramps from overuse.​\n\nRare Serious: Hypokalemia, paradoxical bronchospasm, or severe tachycardia—seek immediate care.​\n\nAvoid in hypersensitivity, uncontrolled arrhythmias, or with beta-blockers. Use cautiously in pregnancy (Category C), hyperthyroidism, diabetes, or hypertension; taper during weaning.​\n\nDosage Guidelines and Best Practices\nFor adults/children >12 years: 0.31-0.63 mg nebulized 3-4 times daily; children 2-12 years: half dose. Always dilute, use fresh solution, and clean nebulizer post-use. Combine with anti-inflammatories for chronic management; do not exceed recommended frequency.​\n\nConclusion: Breathe Easier with THEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg\nTHEO-SLO LEVO LD Levosalbutamol Respiratory Solution 0.31 mg transforms respiratory care by offering swift, reliable bronchodilation for asthma, COPD, and bronchospasm across age groups. Its selective action, nebulizer compatibility, and safety profile make it a cornerstone for symptom relief and lung health preservation. Consult healthcare providers for integrated therapy to achieve optimal breathing freedom and prevent exacerbations.​\n\n", "price": 30.0, "discountamount": 9.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2235, "imageuri": "https://productimages.withfloats.com/actual/693410b81213a99c808c771d.png", "tileimageuri": "https://productimages.withfloats.com/tile/693410b81213a99c808c771d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-06T11:17:09.692Z", "updatedon": "2025-12-06T11:17:09.692Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/levosalbutamol-respiratory-solution-0-31-mg-/2235", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "THEO-SLO LEVO LD", "category": "", "tags": [ "Levosalbutamol Respiratory Solution 0.31 mg", "nebulization", "improving airflow", "respiratory support", "therapy for asthma", "chronic obstructive pulmonary disease (COPD)" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6932959513286b8c66d8786f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Myoinositol 600mg + Metformin SR 500", "description": "OVOCYST M is a specialized sustained-release tablet combining Myoinositol 600mg and Metformin SR 500mg, primarily designed to address polycystic ovary syndrome (PCOS) and related metabolic issues in women. This formulation from Steris Healthcare Pvt Ltd targets insulin resistance, hormonal imbalances, and ovulatory dysfunction, making it a go-to option for restoring reproductive wellness. By improving insulin sensitivity and ovarian function, OVOCYST M supports regular cycles and fertility outcomes effectively.​\n\nProduct Composition and Mechanism\nOVOCYST M features Myoinositol 600mg, a natural insulin signaling mediator that enhances cellular health and oocyte quality in PCOS patients. Paired with Metformin SR 500mg, a sustained-release biguanide that lowers hepatic glucose production and boosts peripheral insulin uptake, this duo tackles root causes like hyperinsulinemia. The SR technology ensures gradual release, minimizing digestive upset while providing prolonged metabolic support throughout the day.​\n\nThis synergistic action restores ovulatory cycles by balancing hormones such as FSH and LH, reducing androgen excess common in PCOS. Women experiencing anovulation or irregular menses find OVOCYST M particularly beneficial as it promotes follicular development without aggressive interventions.​\n\nKey Uses of OVOCYST M\nOVOCYST M excels in managing PCOS symptoms, including irregular menstrual cycles and infertility linked to insulin resistance. Healthcare providers often prescribe it for hyperandrogenism, where elevated male hormones cause hirsutism or acne, alongside metabolic syndrome features like obesity.​\n\nSupports fertility treatments by improving egg quality and implantation rates in assisted reproduction.​\nAids weight management in PCOS by curbing insulin-driven fat accumulation.​\nRegulates blood sugar in prediabetic women with PCOS, preventing progression to type 2 diabetes.​\nTypically taken once or twice daily with meals, the dosage aligns with physician guidance for optimal results over 4-12 weeks.​\n\nMajor Benefits for PCOS and Beyond\nOne standout advantage of OVOCYST M is its ability to normalize ovulation, with studies showing improved cycle regularity in up to 70-80% of users. By enhancing insulin sensitivity, it reduces hyperinsulinemia, alleviating symptoms like fatigue and cravings that hinder daily life.​\n\nPromotes modest weight loss (2-5kg over months) through better metabolic control, boosting self-esteem and mobility.​\n\nEnhances fertility by maturing oocytes and lowering miscarriage risks in PCOS pregnancies.​\n\nLowers androgen levels, clearing skin issues and reducing unwanted hair growth for aesthetic and emotional relief.​\n\nLong-term use under supervision sustains these gains, fostering holistic health improvements like better energy and mood stability.​\n\nPotential Side Effects and Precautions\nWhile generally well-tolerated, OVOCYST M may cause mild gastrointestinal effects such as nausea, flatulence, or a metallic taste from Metformin. These often subside with time or food intake, thanks to the SR formulation's gentler profile.​\n\nRare but serious risks include lactic acidosis in those with kidney/liver issues, warranting avoidance in such cases. Precautions involve monitoring blood sugar, avoiding during acute illnesses, and consulting doctors if pregnant or breastfeeding.​\n\nCommon: Bloating or diarrhea, manageable by starting low dose.​\n\nConsult promptly for persistent vomiting or weakness.​\n\nConclusion\nOVOCYST M stands as a reliable, science-backed ally for women battling PCOS, insulin resistance, and fertility hurdles through its potent Myoinositol 600mg and Metformin SR 500mg blend. Delivering tangible benefits like restored cycles, weight control, and enhanced conception chances, it empowers proactive reproductive health management. Always pair with lifestyle tweaks like balanced diet and exercise for peak efficacy, and rely on professional oversight for safe, sustained results—transforming challenges into opportunities for vitality.", "price": 257.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2233, "imageuri": "https://productimages.withfloats.com/actual/693295fa395d93bf6f980d94.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/693295fa395d93bf6f980d94.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-05T08:19:33.812Z", "updatedon": "2025-12-05T08:19:33.812Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/myoinositol-600mg-metformin-sr-500/2233", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "OVOCYST M", "category": "Gynaecology", "tags": [ "Myoinositol 600mg and Metformin SR 500mg", "polycystic ovary syndrome (PCOS)", "OVOCYST M supports regular cycles and fertility" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }